Microbial tryptamine as a causative cofactor of incurable cell death diseases of unknown etiology

Microbial tryptamine as a causative cofactor of incurable cell death diseases of unknown etiology: The cost of related healthcare in the US and worldwide investigates microbial tryptamine and its role in a range of diseases, such as Alzheimer's disease and Parkinson's disease, while also examining the economic burden of these conditions on healthcare systems globally. The book begins with an examination of microbial tryptamine's significance across neurodegenerative diseases, cancers and gastrointestinal conditions. It covers the implications of tryptamine in cell and organ transplantation, as well as the roles of diet and environment in tryptamine-induced disease progression. Additionally, the latest advances in treatment and prevention are considered. It then provides a critical analysis of expenditure on diseases related to tryptamine-induced cell toxicity and neurodegeneration, alongside an evaluation of current funding and market analysis. Following this, the author delves into research-related issues that may hinder biomedical progress, such as competition, plagiarism, and retractions of funded peer-reviewed articles. Collaboration between researchers and medical doctors is also examined. The book concludes with the author's own personal narrative and recommendations, emphasizing the need for open discussions to drive urgent changes in biomedical research funding and review processes. This book is suitable for biomedical experts and advanced students working with microbial tryptamine, as well as relevant funding agencies, aiming to spark discussion concerning the necessary reforms in funding priorities and practices related to research on microbial tryptamine and its significance for disease.

• Explores microbial tryptamine in diseases like cancer, Alzheimer's disease and Parkinson's disease, and its effects on the gut microbiome
• Analyses research funding related to tryptamine-induced diseases of unknown etiology, advocating for the need to invest in further treatment and laboratory diagnostic tests
• Addresses systemic issues in biomedical research and the need to improve scientific integrity
• Explores healthcare expenditures linked to tryptamine-associated pathologies